Account
Articles
28.04.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Insider Insights
27.04.2022
Optimised NICE recommendations

According to the ABPI, over the last 20 years, 82% of technology appraisal recommendations have been...

Read more
Insider Insights
19.04.2022
Payment model to be launched for antibiotics

The UK looks set to become the first country in the world to use a subscription-style payment model ...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Insider Insights
24.03.2022
“First of its kind” MAA leads to NICE approval

The draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...

Read more
Insider Insights
21.03.2022
Early access agreement

Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...

Read more
Insider Insights
15.03.2022
NICE presents three-year international strategy

Two NICE teams (NICE International and the Science Policy and Research Programme) will act as key en...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more
News
09.03.2022
PMA Insights; Week 10

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
09.03.2022
First drug to receive positive recommendation from

Amgen’s Lumykras (sotorasib) has become the first active new technology to come through the Innova...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.